1. Home
  2. Browse
  3. HRA001948
HRA001948
   HRA001948.xlsx
Title:
Sirpa restrains antitumor immunity by modulating the tumor immune microenvironment
Release date:
2022-02-22
Description:
By performing single-cell RNA sequencing (scRNA-seq) of tumor-infiltrating immune cells (TIICs) from colorectal cancer (CRC) patients, we found that macrophages and granulocytic myeloid-derived suppressor cells (gMDSCs) displaying the highest immune-inhibitory signatures were the most increased immunocytes in tumors compared to corresponding normal tissue. Tumor-infiltrating myeloid cells exhibited significantly increased expression of ITIM-bearing receptors such as SIRPA, CLEC4A and SIGLEC9. Intriguingly, Sirpa-/- mice but not Clec4a2-/- or Siglece-/- mice were more resistant to tumor progression than wild-type (WT) mice. These findings suggest that Sirpa deletion enhances innate and adaptive immune activation in the TIME; thus, Sirpa blockade could be a promising strategy to improve cancer immunotherapy.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA007578
Study type:
Disease Study
Disease name:
colorectal cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC000042
DAC name:
SUSTECH_SCPM
Contact person:
Jin Wenfei Jin
Email:
jinwf@sustech.edu.cn
Description:
SIngle-cell Sequencing in Precison Medicine
Individuals & samples
Files
Request Data
Submitter:   Jin Wenfei / jinwf@sustech.edu.cn
Organization:   Southern University of Science and Technology
Submission date:   2022-02-15
Requests:   1